Nick Giannasi joins Linden as an Operating Partner
Chicago, IL (February 13, 2023) – Linden Capital Partners, a Chicago-based private equity firm focused exclusively on healthcare, today announced that Nick Giannasi joined the firm as an Operating Partner. Mr. Giannasi will support Linden’s healthcare technology and pharma services efforts with focuses around data, artificial intelligence, and product development. Mr. Giannasi is an accomplished executive with over 20 years of healthcare technology experience. Most recently, Mr. Giannasi served as the Chief Product Officer for Ciox and Head of Demand Side Product for Datavant, a healthcare technology company that connects the world’s data to improve patient outcomes.
Prior to Ciox and Datavant, Mr. Giannasi served as EVP, Chief AI Officer, Chief Data Officer and SVP of Data Sciences and Product Management at Change Healthcare, where he defined and led the execution of a strategy for applied artificial intelligence and also led the company’s enterprise-wide data quality and life-cycle management. Before that, Nick served as Vice President of Life Sciences Product Strategy at Oracle, where his team delivered growth via product development, partnerships, and M&A and oversaw a change from a premises-based to a subscription cloud-based business model. Prior to Oracle, he held various leadership roles at Amersham, Double Twist, and GE Healthcare. He co-founded the biotech company Phenocure LTD.
“Data and artificial intelligence have become increasingly important components of our value creation plans,” said Linden Partner Kam Shah. “Nick has a long history when it comes to applying data and AI to healthcare business models, and we are thrilled for him to join Linden as an Operating Partner.”
“I look forward to partnering with Linden,” said Mr. Giannasi. “During my tenure on the Board of Directors at Aspirion, I have been impressed with Linden’s differentiated value creation model that integrates operating and investment experience. I am excited to work alongside the Linden team with the goal of investing in exceptional businesses that can leverage data, product development, and artificial intelligence.”
Mr. Giannasi holds a Bachelor of Science, with First Class Honors, in Zoology and Biochemistry from the University of Reading, earned his Ph.D. in Molecular, Behavioral, and Morphological Evolution from the University of Wales, and performed post-doctoral research under a Leverhulme Fellowship with Novartis. Mr. Giannasi currently serves as a board member at Aspirion, a Linden portfolio company. He also serves as a board member at Motiva.ai and is a senior advisor to Datavant.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested in over 40 healthcare companies encompassing over 250+ total transactions. The firm has raised over $7 billion in limited partner commitments since inception. For more information, please visit www.lindenllc.com.